Liverpool Skylilne

Pharmacy and Biomolecular Sciences

Dr Raida Al Kassas

Dr Raida Al Kassas

Telephone: 0151 904 6185

ORCID

Publications

Highlighted publications

Hsi S-L, Surman P, Al-Kassas R. 2019. Development of a stability-indicating UPLC method for determination of isotretinoin in bulk drug Pharmaceutical Development and Technology, 24 :189-198 DOI Author Url Publisher Url Public Url

Al Kassas R, Bansal M, Shaw J. 2017. Nanosizing techniques for improving bioavailability of drugs Journal of Controlled Release, 260 :202-212 DOI Author Url Publisher Url Public Url

Cerqueira BBS, Lasham A, Shelling AN, Al-Kassas R. 2017. Development of biodegradable PLGA nanoparticles surface engineered with hyaluronic acid for targeted delivery of paclitaxel to triple negative breast cancer cells Materials Science and Engineering: C, 76 :593-600 DOI Author Url Publisher Url Public Url

Al-Kassas R, Wen J, Cheng AE-M, Kim AM-J, Liu SSM, Yu J. 2016. Transdermal delivery of propranolol hydrochloride through chitosan nanoparticles dispersed in mucoadhesive gel Carbohydrate Polymers, 153 :176-186 DOI Author Url Publisher Url Public Url

Duxfield L, Sultana R, Wang R, Englebretsen V, Deo S, Swift S, Rupenthal I, Al-Kassas R. 2016. Development of gatifloxacin-loaded cationic polymeric nanoparticles for ocular drug delivery PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 21 :172-179 DOI Author Url

Duxfield L, Sultana R, Wang R, Englebretsen V, Deo S, Rupenthal ID, Al-Kassas R. 2016. Ocular delivery systems for topical application of anti-infective agents DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 42 :1-11 DOI Author Url

Seyfoddin A, Sherwin T, Patel DV, McGhee CN, Rupenthal ID, Taylor JA, Al-Kassas R. 2016. Ex vivo and In vivo Evaluation of Chitosan Coated Nanostructured Lipid Carriers for Ocular Delivery of Acyclovir Current Drug Delivery, 13 :923-934 DOI Author Url Publisher Url Public Url

Alzaher W, Shaw J, Al-Kassas R. 2016. Gastroretentive Formulations for Improving Oral Bioavailability of Drugs-Focus on Microspheres and their Production Current Drug Delivery, 13 :646-661 DOI Author Url Publisher Url Public Url

Cerqueira BBS, Lasham A, Shelling AN, Al-Kassas R. 2015. Nanoparticle therapeutics: Technologies and methods for overcoming cancer EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 97 :140-151 DOI Author Url

Tharkar P, Madani AU, Lasham A, Shelling AN, Al-Kassas R. 2015. Nanoparticulate carriers: an emerging tool for breast cancer therapy JOURNAL OF DRUG TARGETING, 23 :97-108 DOI Author Url

Madni A, Sarfraz M, Rehman M, Ahmad M, Akhtar N, Ahmad S, Tahir N, Ijaz S, Al-Kassas R, Loebenberg R. 2014. Liposomal Drug Delivery: A Versatile Platform for Challenging Clinical Applications JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 17 :401-426 DOI Author Url

Kuntworbe N, Ofori M, Addo P, Tingle M, Al-Kassas R. 2013. Pharmacokinetics and in vivo chemosuppressive activity studies on cryptolepine hydrochloride and cryptolepine hydrochloride-loaded gelatine nanoformulation designed for parenteral administration for the treatment of malaria ACTA TROPICA, 127 :165-173 DOI Author Url

Kuntworbe N, Alany RG, Brimble M, Al-Kassas R. 2013. Determination of pKa and forced degradation of the indoloquinoline antimalarial compound cryptolepine hydrochloride PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 18 :866-876 DOI Author Url

Seyfoddin A, Al-Kassas R. 2013. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 39 :508-519 DOI Author Url

Awasthi A, Razzak M, Al-Kassas R, Harvey J, Garg S. 2013. Evaluation of degradation kinetics for abamectin in formulations using a stability indicating method ACTA PHARMACEUTICA, 63 :59-69 DOI Author Url

Journal article

Hsi S-L, Surman P, Al-Kassas R. 2019. Development of a stability-indicating UPLC method for determination of isotretinoin in bulk drug Pharmaceutical Development and Technology, 24 :189-198 DOI Author Url Publisher Url Public Url

Al Kassas R, Bansal M, Shaw J. 2017. Nanosizing techniques for improving bioavailability of drugs Journal of Controlled Release, 260 :202-212 DOI Author Url Publisher Url Public Url

Cerqueira BBS, Lasham A, Shelling AN, Al-Kassas R. 2017. Development of biodegradable PLGA nanoparticles surface engineered with hyaluronic acid for targeted delivery of paclitaxel to triple negative breast cancer cells Materials Science and Engineering: C, 76 :593-600 DOI Author Url Publisher Url Public Url

Al-Kassas R, Wen J, Cheng AE-M, Kim AM-J, Liu SSM, Yu J. 2016. Transdermal delivery of propranolol hydrochloride through chitosan nanoparticles dispersed in mucoadhesive gel Carbohydrate Polymers, 153 :176-186 DOI Author Url Publisher Url Public Url

Duxfield L, Sultana R, Wang R, Englebretsen V, Deo S, Swift S, Rupenthal I, Al-Kassas R. 2016. Development of gatifloxacin-loaded cationic polymeric nanoparticles for ocular drug delivery PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 21 :172-179 DOI Author Url

Duxfield L, Sultana R, Wang R, Englebretsen V, Deo S, Rupenthal ID, Al-Kassas R. 2016. Ocular delivery systems for topical application of anti-infective agents DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 42 :1-11 DOI Author Url

Seyfoddin A, Sherwin T, Patel DV, McGhee CN, Rupenthal ID, Taylor JA, Al-Kassas R. 2016. Ex vivo and In vivo Evaluation of Chitosan Coated Nanostructured Lipid Carriers for Ocular Delivery of Acyclovir Current Drug Delivery, 13 :923-934 DOI Author Url Publisher Url Public Url

Alzaher W, Shaw J, Al-Kassas R. 2016. Gastroretentive Formulations for Improving Oral Bioavailability of Drugs-Focus on Microspheres and their Production Current Drug Delivery, 13 :646-661 DOI Author Url Publisher Url Public Url

Cerqueira BBS, Lasham A, Shelling AN, Al-Kassas R. 2015. Nanoparticle therapeutics: Technologies and methods for overcoming cancer EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 97 :140-151 DOI Author Url

Tharkar P, Madani AU, Lasham A, Shelling AN, Al-Kassas R. 2015. Nanoparticulate carriers: an emerging tool for breast cancer therapy JOURNAL OF DRUG TARGETING, 23 :97-108 DOI Author Url

Svirskis D, Seyfoddin A, Chalabi S, Kim JHI, Langford C, Painter S, Al-Kassas R. 2014. Development of mucoadhesive floating hollow beads of acyclovir with gastroretentive properties PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 19 :571-576 DOI Author Url

Madni A, Sarfraz M, Rehman M, Ahmad M, Akhtar N, Ahmad S, Tahir N, Ijaz S, Al-Kassas R, Loebenberg R. 2014. Liposomal Drug Delivery: A Versatile Platform for Challenging Clinical Applications JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 17 :401-426 DOI Author Url

Kuntworbe N, Ofori M, Addo P, Tingle M, Al-Kassas R. 2013. Pharmacokinetics and in vivo chemosuppressive activity studies on cryptolepine hydrochloride and cryptolepine hydrochloride-loaded gelatine nanoformulation designed for parenteral administration for the treatment of malaria ACTA TROPICA, 127 :165-173 DOI Author Url

Kuntworbe N, Alany RG, Brimble M, Al-Kassas R. 2013. Determination of pKa and forced degradation of the indoloquinoline antimalarial compound cryptolepine hydrochloride PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 18 :866-876 DOI Author Url

Seyfoddin A, Al-Kassas R. 2013. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 39 :508-519 DOI Author Url

Awasthi A, Razzak M, Al-Kassas R, Harvey J, Garg S. 2013. Evaluation of degradation kinetics for abamectin in formulations using a stability indicating method ACTA PHARMACEUTICA, 63 :59-69 DOI Author Url

Awasthi A, Razzak M, Al-Kassas R, Greenwood DR, Harvey J, Garg S. 2012. Isolation and characterization of degradation products of moxidectin using LC, LTQ FT-MS, H/D exchange and NMR ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 404 :2203-2222 DOI Author Url

Awasthi A, Razzak M, Al-Kassas R, Greenwood DR, Harvey J, Garg S. 2012. Separation and Identification of Degradation Products in Abamectin Formulation Using LC, LTQ FT-MS, H/D Exchange and NMR CURRENT PHARMACEUTICAL ANALYSIS, 8 :415-430 DOI Author Url

Abdelkader H, Wu Z, Al-Kassas R, Alany RG. 2012. Niosomes and discomes for ocular delivery of naltrexone hydrochloride: Morphological, rheological, spreading properties and photo-protective effects INTERNATIONAL JOURNAL OF PHARMACEUTICS, 433 :142-148 DOI Author Url

Awasthi A, Razzak M, Al-Kassas R, Harvey J, Garg S. 2012. An Overview on Chemical Derivatization and Stability Aspects of Selected Avermectin Derivatives CHEMICAL & PHARMACEUTICAL BULLETIN, 60 :931-944 DOI Author Url

Abdelkader H, Ismail S, Hussein A, Wu Z, Al-Kassas R, Alany RG. 2012. Conjunctival and corneal tolerability assessment of ocular naltrexone niosomes and their ingredients on the hen's egg chorioallantoic membrane and excised bovine cornea models INTERNATIONAL JOURNAL OF PHARMACEUTICS, 432 :1-10 DOI Author Url

Fathabadi EG, Shelling AN, Al-Kassas R. 2012. Nanocarrier systems for delivery of siRNA to ovarian cancer tissues EXPERT OPINION ON DRUG DELIVERY, 9 :743-754 DOI Author Url

Kuntworbe N, Martini N, Shaw J, Al-Kassas R. 2012. Malaria Intervention Policies and Pharmaceutical Nanotechnology as a Potential Tool for Malaria Management DRUG DEVELOPMENT RESEARCH, 73 :167-184 DOI Author Url

Kuntworbe N, Al-Kassas R. 2012. Design and In Vitro Haemolytic Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles as a Novel Approach for the Treatment of Malaria AAPS PHARMSCITECH, 13 :568-581 DOI Author Url

Awasthi A, Razzak M, Al-Kassas R, Greenwood DR, Harvey J, Garg S. 2012. Separation and identification of degradation products in eprinomectin formulation using LC, LTQ FT-MS, H/D exchange, and NMR JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 63 :62-73 DOI Author Url

Al Kassas R, Kuntworbe N, Alany R, Brimble M, Martini N. 2011. Isolation and development of an HPLC method for the detection and quantification of cryptolepine and its application in the determination of the total cryptolepine content in the root powder of Cryptolepis sanguinolenta. Perry G. Pharmacology & Pharmacy, 3

Abdelkader H, Wu Z, Al-Kassas R, Brown JE, Alany RG. 2011. Preformulation characteristics of the opioid growth factor antagonist-naltrexone hydrochloride: stability and lipophilicity studies JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 21 :157-163 DOI Author Url

Seyfoddin A, Shaw J, Al-Kassas R. 2010. Solid lipid nanoparticles for ocular drug delivery DRUG DELIVERY, 17 :467-489 DOI Author Url

Al-Kassas RS, El-Khatib MM. 2009. Ophthalmic controlled release in situ gelling systems for ciprofloxacin based on polymeric carriers DRUG DELIVERY, 16 :145-152 DOI Author Url

Al-Kassas RS, Al-Gohary OMN, Al-Faadhel MM. 2007. Controlling of systemic absorption of gliclazide through incorporation into alginate beads INTERNATIONAL JOURNAL OF PHARMACEUTICS, 341 :230-237 DOI Author Url

Al-Kassas R. 2004. Design and in vitro evaluation of gentamicin-Eudragit microspheres intended for intra-ocular administration JOURNAL OF MICROENCAPSULATION, 21 :71-81 DOI Author Url

Al-Kassas R. 2003. Interaction study between mebeverine hydrochloride, isoniazid and certain polymers used to prepare multiparticulate delivery systems using differential scanning calorimetry STP PHARMA SCIENCES, 13 :359-366 Author Url

Al-Kassas RS, Rezk NJ. 2003. Enterotoxigenic E-coli colonization factor antigen (CFA/II)-loaded polyisobutylcyanoacrylate nanoparticles for oral immunization STP PHARMA SCIENCES, 13 :93-98 Author Url

Safwat SM, Al-Kassas RS. 2002. Evaluation of gentamicin-Eudragit microspheres as ophthalmic delivery systems in inflamed rabbit's eyes STP PHARMA SCIENCES, 12 :357-361 Author Url

Al Kassas R. 2000. Controlled-release theophylline suppositories containing bioadhesive microspheres Bulletin of Faculty of Pharmacy, Cairo University,

Al-Gohary OMN, Al-Kassas RS. 2000. Stability studies of aspirin-magaldrate double layer tablets Pharmaceutica Acta Helvetiae, 74 :351-360 DOI Author Url

Su XY, Al-Kassas R, Li Wan Po A. 1994. Statistical modelling of ibuprofen release from spherical lipophilic matrices European Journal of Pharmaceutics and Biopharmaceutics, 40 :73-76

Al-Kassas RS, Gilligan CA, Li Wan Po A. 1993. Processing factors affecting particle size and in vitro drug release of sustained-release ibuprofen microspheres International Journal of Pharmaceutics, 94 :59-67 DOI

Gupta J, Tao JQ, Garg S, Al-Kassas R. Design and Development of an <i>in Vitro</i> Assay for Evaluation of Solid Vaginal Dosage Forms Pharmacology & Pharmacy, 02 :289-298 DOI

Al Kassas R, Shelling A. pH- sensitive nanoparticles developed and optimized using factorial design for improving oral absorption of gliclazide Asadullah A, Buchanan C. Drug Development and Industrial Pharmacy,

Chapters

Awasthi A, Razzak M, Al-Kassas R, Harvey J, Garg S. 2013. Analytical Profile of Moxidectin Profiles of Drug Substances, Excipients and Related Methodology 38 :315-366 DOI Author Url

Seyfoddin A, Al-Kassas R. 2011. Biodegradable polymers for controlled delivery of bioactive macromolecules Biodegradable Polymers: Processing, Degradation and Applications :471-500 9781612095349

Engagement & Impact

External PGR Supervision - completed students:

Liverpool University, Other, Biodegradable polymeric nanoparticles for the delivery of dexamethasone to posterior eye for the treatment of retinal diseases. 2020

Industrial connections:

Quay Pharma, Collaboration with Dr Alison Foster on project involves development of novel, industry-relevant methods of manufacturing enabled nanoparticle formulations of poorly soluble drugs to improve and enhance delivery of the drug to the gastro-intestinal tract.. 2019

Douglas Pharmaceuticals in New Zealand, Media milling and design of experiment. 2018

Research Grants Awarded:

COVT organization, Design of gliclazide tableted microspheres using hydrophilic polymer: effect of excipients on tablets properties, Monira AlFadel (King saud University), Omaimah AlGohary (King saud University), Grant value (£): Travel grant (£250 + registration fees), Duration of research project: 2 days conference. 2019

Auckland Academic Health Alliance, New and effective method for the treatment of cystic fibrosis using nanotechnology, Prof John Kolbe, Prof Andrew Shelling,, Grant value (£): NZ$10,000, Duration of research project: 2 years. 2016

Cure Kids, Novel creams to treat antibiotic-resistant Staphylococcal skin infections, Dr Siouxsie Wiles, DR Simon Swift, Grant value (£): NZ$49,130, Duration of research project: one year. 2015

Maurice & Phyllis Paykel Trust, Hyaluronic acid engineered silica PLGA nanoparticles for improving therapeutic efficacy and delivery of paclitaxel to breast cancer, prof Andrew Shelling, Grant value (£): £5000, Duration of research project: 2 years. 2015

Douglas Pharmaceuticals, media milling and design of experiment, Peter Surman, Douglas Pharmaceutical industry, Grant value (£): Student fees + consumables, Duration of research project: one year. 2015

Maurice Phyllis and Paykel-Travel grant, Enhanced solubility and dissolution rate of gatifloxacin by solid dispersion technique, Grant value (£): NZ$3000. 2015

University of Auckland staff fund (PBRF), Functionalized lipid nanoparticles for the delivery of paclitaxel to ovarian cancer cells., Prof Andrew Shilling, Grant value (£): NZ$1000, Duration of research project: 3 months. 2014

University of Auckland, Distinguished Visitor Award, Grant value (£): NZ$5800. 2013

Higher Education Commission of Pakistan, Development of siRNA loaded folate nanoparticles for the treatment of ovarian cancer, Andrew Shelling, Grant value (£): NZ$40,000, Duration of research project: 6 months. 2013

Nurture Foundation, Nanocarriers for the delivery of siRNA to ovarian cancer, Andrew Shelling, Grant value (£): NZ$10,000. 2012

The University of Auckland-Faculty Research Development Fund (FRDF), Improving ocular penetration and bioavailability of acyclovir using solid lipid nanoparticles., Charles McGhee, John Taylor, Grant value (£): NZ$48000, Duration of research project: 2 years. 2011

The University of Auckland-staff research fund- for summer projects, Formulation of triclosan-PLGA nanoparticles for treatment of periodontal disease, Grant value (£): 2000, Duration of research project: 3 months. 2010

The University of Auckland-staff research fund- for summer projects, Stability and compatibility of new olive oil/fish oil emulsions in parenteral nutrition admixtures (University of Auckland), Gill Hardy, Grant value (£): NZ$4000, Duration of research project: 3 months. 2010

The University of Auckland-faculty Research Development Fund-New Staff fund, Design and development of cryptolepine loaded gelatin nanoparticles for treatment of malaria, Margeret Brimble, Grant value (£): NZ$3000. 2010

Bioencapsulation Research Group, Travel grant-, Grant value (£): Euro 600. 2010

New Zealand Pharmacy Education Foundation (NZPERF), Evaluation of quality of medicines imported into New Zealand, Sanjay Garg, Grant value (£): 5000. 2009

New Zealand Pharmacy Education Foundation (NZPERF), Development of acyclovir loaded solid lipid nanopartilces intended for ocular administration, Grant value (£): 5000. 2009

Knowledge transfer partnership (KTP), To develop novel, industry-relevant methods of manufacturing enabled nanoparticle formulations of poorly soluble drugs to improve and enhance delivery of the drug to the gastro-intestinal tract., Matt Roberts, Quay Pharma, Grant value (£): £ 181,383, Duration of research project: 2 years.

The University of Auckland-staff research fund- for summer projects, Design and evaluation of antibacterial patches for treatment of periodontal disease, Grant value (£): NZ$4000, Duration of research project: 3 months.

Conference presentation:

Design of gliclazide tableted microspheres using hydrophilic polymer: effect of excipients on tablets properties, 5th CVOT Summit 2019, Munich/Germany, Poster presentation. 2019

Hyaluronic Acid Coated PLGA Nanoparticles for Target Delivery of Paclitaxel to Triple Negative Breast Cancer, Australian Pharmacy science association (APSA) conference, Australia, Poster presentation. 2015

“Enhanced solubility and dissolution rate of gatifloxacin by solid dispersion technique., Controlled Release Society conference (CRS), Edinburgh, Scotland, Poster presentation. 2015

Development of Gatifloxacin loaded Eudragit nanoparticles for ocular drug delivery, 41st Annual Meeting and Exposition of the Controlled Release Society, Chicago, USA, Poster presentation. 2014

Effect of cross-linking agent on the characteristics of chitosan nanoparticles designed for the delivery of siRNA to ovarian cancer tissues, XXI International Conference on Bioencapsulation, Berlin, Germany, Berlin, Germany, Poster presentation. 2013

. Evaluation of a Novel Lipid Based Nanoparticulate System for Ocular Drug Delivery., 40th annual meeting & exposition of the Controlled Release Society, Hawaii Convention Center in Honolulu, Hawaii, Honolulu, Hawaii, Oral presentation. 2013

Membership of professional bodies:

Member, The British Society for Nanomedicine. 2019

External collaboration:

Quay Pharma Industry, Dr Alison Foster. 2019

Liverpool University, University of Newcastle, St Paul Eye Hospital, Prof David Steel, Dr Victoria Kearns, Dr Teresa Sandinha. 2019

The University of Auckland, Prof Andrew Shelling. 2019

Other invited event:

Oral presentation, Paris-Sud University-School of Pharmacy, Oral presentation entitled [Nanotechnology for improving bioavailability of medicine].. 2016

Invited speaker by Nurture Foundation, faculty of Mmedical and Health Science-University of Auckland, I was invited by Nurture Foundation as a speaker. The title of my presentation was [Nanotechnology for targeting gene to ovarian cancer cells for the treatment of ovarian cancer].. 2015

External reviewer for grant application, La Marató de TV3 Foundation, External reviewer to grant application funded by La Marató de TV3 Foundation. The title of the application is Nanobots to fight cancer: Design of multifunctional nanoparticles for combined chemotherapy, immunotherapy and radiation therapy in a single carrier for the treatment of liver tumours.. 2013

External PGR examinations performed:

University of Queensland, PhD, The development of Cyclodextrin‐Poly(acrylic acid) Conjugates for Sustained Drug. 2013

External committees:

Saudi Pharmaceutical Society, Saudi Pharmaceutical Society, member. 1989